



VACCINE
WORLD ASIA CONGRESS 2026
South East Asia



BIOLOGICS
WORLD
SOUTH EAST
ASIA 2026

Southeast Asia's Only Co-Located Vaccine & Biologics Congress



14 - 15 October 2026 Sheraton Grand Jakarta Gandaria City Hotel,
Indonesia

OFFICIAL EVENT BROCHURE

<https://infohub.imapac.com/vwsea-bwsea-2026-brochure>

Table of Contents

About the Event	3
Sponsors & Media Partners	4
2026 Speakers	5
Agenda At A Glance	9
Agenda	10
Expected Audience Snapshot	29
Who Should Sponsor?	30
Why Sponsor This Event?	30
Our Past Partners	31
Add to Calendar	32
Registration Form	33
About IMAPAC	34

EVENT CONTACTS

HEAD OF PRODUCTION

Lara Santiago

lara.santiago@imapac.com
+639176210686

CONFERENCE PRODUCER

Anusha Shirshyad

anusha.shirshyad@imapac.com
+6569645109

PORTFOLIO SPECIALIST

Caterin Sanggita

caterin.sanggita@imapac.com
+6569836137 | +62811654788

BUSINESS DEVELOPMENT MANAGER

Nathan Grace Niño

nathan.grace@imapac.com
+6569836134

EVENT HIGHLIGHTS

300+

ATTENDEES

130+

COMPANIES

60+

SPEAKERS

DATE & VENUE

14 - 15 October 2026

Sheraton Grand Jakarta Gandaria City Hotel
Indonesia

About the Event

Vaccine World Asia Congress – Southeast Asia and Biologics World Southeast Asia return in 2026 as a single co-located platform, uniting Southeast Asia's vaccine and therapeutic-biologics communities under one roof in Jakarta. Together they convene policymakers, manufacturers, researchers, CDMOs, regulators, investors and technology partners driving the region's fastest-growing areas of biopharma.

The Vaccine Congress spotlights infectious-disease immunisation, next-generation platforms (mRNA, recombinant, viral vectors,

thermostable formulations) and the drive toward regional vaccine self-sufficiency, while Biologics World Southeast Asia focuses on the full therapeutic-biologics value chain — monoclonal antibodies, biosimilars, ADCs and protein therapeutics, from R&D and translational science through bioprocessing, manufacturing scale-up and market access. Co-locating the two enables cross-industry exchange across the broader biopharmaceutical ecosystem while preserving each event's distinct scientific and commercial agenda — positioning ASEAN as a competitive hub for both vaccines and biologics.

Sponsors & Media Partners

GOLD



BRONZE



EXHIBITORS



ASSOCIATE



Business Development Manager:

Nathan Grace Niño · nathan.grace@imapac.com · +6569836134

2026 SPEAKERS

VACCINE WORLD ASIA CONGRESS 2026 SOUTH EAST ASIA



Badarulhisam Abdul Rahman, PhD
Chief Scientific Officer
Pharmaniaga Berhad
MALAYSIA



Zainab Sadat
General Manager, Vaccines,
Southeast Asia & India MCO
Sanofi
SINGAPORE



Meenu Batolar
Global Regulatory Affairs Asia
Pacific Lead
CEPI
SINGAPORE



Dr. Neni Nurainy
Head of Translational
Development of Life Science
Product
Bio Farma
INDONESIA



M. Indra Lamora
Director – Anti Infectious
Department
Etana Biotechnologies
INDONESIA



Indriana Permatasari
Project Manager
**International Vaccine Institute
(IVI)**
INDONESIA



Dr. Soleh Ayubi
Chief of Country Representative
PATH
INDONESIA



Dr. Jetsumon Sattabongkot Prachumsri
Director, Mahidol Vivax
Research Unit
Mahidol University
THAILAND



Dr. Indra Rudiansyah
Project Lead, mRNA Vaccine
Programme
Bio Farma
INDONESIA



Dr. Wenshuo Zhou
Senior Director R&D & CEO
Scientific Assistant
Abogen Biosciences
CHINA



Prasen Adya
Deputy Director
Serum Institute of India
INDIA



Dr. Nicholas Lim
Medical Head, RSV Vaccines
India & Southeast Asia MCO
Sanofi
SINGAPORE



Dr. Seyed Reza Banihashemi
Director of R&D
**Razi Vaccine & Serum Research
Institute**
IRAN



Xiaoyuan Zhao
International Clinical Project
Management Expert, R&D
Division
CanSino Biologics Inc.
SWITZERLAND



Mr. Mohd Fadhil bin Razmi
Head of Cluster, Vaccine &
Logistics, Malaysia Vaccine
Project Office (MVPO)
**Ministry of Science, Technology
& Innovation (MOSTI)**
MALAYSIA



Claire Chong
Technical application manager
**Tofflon Science and Technology
Group Co., Ltd.**
SINGAPORE

VACCINE WORLD ASIA CONGRESS 2026 SOUTH EAST ASIA



Sophie Lam

Regional Business Manager
**BD Southeast Asia Biopharma
System**
🇸🇬 SINGAPORE



**Yuli Fitriyani
Syoemantri**

Head of BCG Vaccine
Production Department
Bio Farma
🇮🇩 INDONESIA



Dr. Martina Ochs

Programme Leader - RNA
Programme
CEPI
🇬🇧 UNITED KINGDOM



Dr. Mrunal Shetye

Chief of Health
**UNICEF Indonesia Country
Office**

BIOLOGICS WORLD ASIA CONGRESS 2026 SOUTH EAST ASIA



Abhijit Kayal

Senior Scientist II

Schrodinger

INDIA



Sophie Lam

Regional Business Manager
BD Southeast Asia Biopharma
System

SINGAPORE



Bobby George

Senior Vice President, Head
Regulatory Affairs
Reliance Life Sciences

INDIA



Butet Manurung

Managing Director
Jakarta Biopharmaceutical
Industry (JBio)

INDONESIA



Cheng Yi (Jerry) Kuo

Vice General Manager

UWELL Biopharma

TAIWAN



Chethan A J

Assistant Director - QA & RA,
Center for Ocular Regeneration
(CORE)

Brien Holden Eye Research
Center (BHERC)

INDIA



**Christian Karol
Saputra**

Head of Corporate Relation &
Strategic Affair

Etana Biotechnologies

INDONESIA



Deepak Mukherjee

Country Medical Director

Roche

INDONESIA



Doo Young Jung

Chief Executive Officer

PinotBio

SOUTH KOREA



Kurt Wee

Chief Executive Officer

Celligenics

SINGAPORE



Lutfhi Zarkasyi

Director of Manufacturing

Kalbio Global Medika

INDONESIA



Nicolas Husser

Head of Operations

Kalbio Global Medika

INDONESIA



Rakhmat Budi Yuwono

Quality Director

Etana Biotechnologies

INDONESIA



**Dr. Seyed Reza
Banihashemi**

Director of R&D

Razi Vaccine & Serum Research
Institute

IRAN



Sandy Qlintang

President Director

Bifarma Adiluhung

INDONESIA



Shanti Marlina Sibuea

Acting Director of Production
Control of Drugs, Narcotics,
Psychotropics, and Precursors
Indonesian National Agency of
Drug and Food Control (Badan
POM/BPOM)

INDONESIA

BIOLOGICS WORLD ASIA CONGRESS 2026 SOUTH EAST ASIA



Syifa Mutiara Hersista

Digital Tech Research Manager

Bio Farma

 **INDONESIA**



Vaibhav Dubey

Senior General Manager

Sun Pharmaceuticals

 **INDIA**



Vipul Doshi

Chief Quality and Compliance
Officer

Zydus Lifesciences

 **INDIA**



Yagna Praveen

Asst Vice President, Head of
Strategic Research

Pharmaniaga

 **MALAYSIA**

Agenda At A Glance

CONFERENCE DAY 1 14TH OCTOBER 2026		CONFERENCE DAY 2 15TH OCTOBER 2026	
			
Opening Plenary Building Southeast Asia's Biologics & Vaccine Ecosystem		mRNA, Viral Vector & Novel Platforms for Fast-Response Vaccines	Bioprocessing & Manufacturing Innovation in Southeast Asia
MORNING TEA, EXHIBITION VIEWING, POSTER PRESENTATIONS & 1-1 ATTENDEE NETWORKING			
Next-Generation Vaccine Discovery & Platform Technologies	Therapeutic Biologics Market Growth & Commercial Opportunities in Southeast Asia	Vaccine Showcase Emerging & Re-Emerging Infectious Diseases in Southeast Asia	CDMO, Technology Transfer & Manufacturing Partnerships in Asia
LUNCH, EXHIBITION VIEWING, POSTER PRESENTATIONS & 1-1 ATTENDEE NETWORKING			
Clinical Trials & Regulatory Harmonization in SEA	R&D, Clinical Development & Translational Science for Biologics	Vaccine Distribution & Cold Chain	Future Modalities Next-Generation Cell & Advanced Biologics
AFTERNOON TEA, EXHIBITION VIEWING, POSTER PRESENTATIONS & 1-1 ATTENDEE NETWORKING			
Scaling Bio-manufacturing Capacity & Technology Transfer Across SEA	Clinical Adoption, Reimbursement & Market Access for Therapeutic Biologics	Leadership Panel Can Southeast Asia Become a Global Biomanufacturing Powerhouse?	
END OF CONFERENCE			

Vaccine World Asia Congress 2026

Biologics World Asia Congress 2026

8:50

IMAPAC Opening Remarks

8:55

Chairman Opening Remarks



Butet Manurung

Managing Director, Jakarta Biopharmaceutical Industry (JBio)



Opening Plenary: Building Southeast Asia's Biologics & Vaccine Ecosystem

9:00

Panel Discussion: Building a Resilient Biologics & Vaccine Ecosystem in Southeast Asia: From Capacity to Capability

- Bridging gaps across R&D, manufacturing, and supply chain to create a connected regional ecosystem
- Public-private partnerships: Aligning governments, industry, and academia to accelerate innovation
- Strengthening regional self-sufficiency vs. global dependency in vaccine and biologics production
- Talent, infrastructure, and policy: What's needed to position Southeast Asia as a global hub

MODERATOR



Dr. Mrunal Shetye

Chief of Health, UNICEF Indonesia Country Office

PANELISTS



Dr. Soleh Ayubi

Chief of Country Representative, PATH



Mr. Mohd Fadhl bin Razmi

Head of Cluster, Vaccine & Logistics, Malaysia Vaccine Project Office (MVPO), Ministry of Science, Technology & Innovation (MOSTI)



Prasen Adya

Deputy Director, Serum Institute of India



Meenu Batolar

Global Regulatory Affairs Asia Pacific Lead, CEPI

Vaccine World Asia Congress 2026

Biologics World Asia Congress 2026

9:50

Accelerating the 100 Days Mission: Leveraging Platform Evidence and Innovative Safety Frameworks for Rapid Vaccine Development

- Harnessing platform technologies to accelerate vaccine development through the strategic use of prior CMC, non-clinical, and clinical data.
- Advancing regulatory preparedness by enabling reliance on platform knowledge, standardized approaches, and outbreak-responsive regulatory pathways
- Implementing risk-based safety frameworks that support Emergency Use Listing (EUL) while maintaining robust benefit-risk oversight
- Building evidence at the pace of pandemics through platform-specific safety surveillance, standardized AESI definitions, and real-world data generation

**Meenu Batolar**

Global Regulatory Affairs Asia Pacific Lead, CEPI

10:15

Morning Tea Break, Exhibition Viewing & 1-1 Attendee Networking

Vaccine World Asia Congress 2026



**Next-Generation
Vaccine Discovery
& Platform
Technologies**

SESSION CHAIR



Prasen Adya

Deputy Director, Serum Institute of India

Biologics World Asia Congress 2026



**Therapeutic
Biologics Market
Growth &
Commercial
Opportunities in
Southeast Asia**

11:00

**From Pathogen to Platform:
Accelerating Vaccine Discovery in
the Post-Pandemic Era**

- What are the advantages of the RNA modality in infectious disease development and broader therapeutic areas?
- How can we achieve deep optimization of RNA technologies?
- In which potential areas might RNA technology outperform other modalities?



Dr. Wenshuo Zhou

Senior Director R&D & CEO Scientific Assistant, Abogen Biosciences

11:00

**Accelerating Biologics Innovation in
Indonesia: From Research to Market
Access**

- Identifying gaps in the drug development process and potential solutions
- Exploring the end-to-end biologics development pipeline, from upstream research through commercialization and market access
- Examining the role of pentahelix collaboration in accelerating biologics innovation



Christian Karol Saputra

Head of Corporate Relation & Strategic Affair, Etana Biotechnologies

Vaccine World Asia Congress 2026

11:25

V2P – New generation Vaccines Delivery Solutions

- Vaccine packaging trends and future-ready delivery solutions
- Benefits of converting from Vial to prefilled for vaccine safety and efficiency
- Innovations in vaccine administration and immunization access
- How BD's integrated service and solution can support pharma companies for sustainable approaches to vaccine delivery and deployment



Sophie Lam

Regional Business Manager, BD Southeast Asia Biopharma System

Biologics World Asia Congress 2026

11:25

Building Regional Biomanufacturing Capacity: From Infrastructure & Operations to Manufacturing Scale-Up (TBC)



Reserved for Nicolas Husser

Head of Operations, Kalbio Global Medika

11:50

Strategic Framework for Designing ADCs with a Better Therapeutic Window

- Building a quantitative model to explain discrepancies between the preclinical and clinical therapeutic windows of Topli payload ADCs
- Applying insights from the quantitative model to design new payloads for ADCs with an improved therapeutic window
- Expanding the application of quantitative models to enable the development of next-generation ADCs



Doo Young Jung

Chief Executive Officer, PinotBio

11:50

Lunch, Exhibition Viewing & 1-1 Attendees Networking

12:15

Lunch, Exhibition Viewing & 1-1 Attendees Networking

Vaccine World Asia Congress 2026



Clinical Trials & Regulatory Harmonization in SEA

1:30

The Future of Needle-Free Immunization: Advances in Intranasal and Mucosal Vaccines

- Advancing intranasal and mucosal vaccine platforms as alternatives to traditional injectable vaccines
- Understanding the potential of mucosal immunity for preventing infection and transmission
- Addressing R&D, clinical, regulatory, and manufacturing challenges in developing needle-free vaccines
- Exploring opportunities to improve vaccine accessibility, acceptance, and rapid deployment through next-generation delivery approaches



Dr. Seyed Reza Banihashemi

Director of R&D, Razi Vaccine & Serum Research Institute

Biologics World Asia Congress 2026



R&D, Clinical Development & Translational Science for Biologics

1:40

Clinical Development & Translational Science for Advanced Biologics

- Stages of translational science and the clinical development pathway
- Why advanced biologics translate differently: addressing the translation gap through quality by design (qbd)
- Key risks in clinical development & translational research: how translational teams can mitigate them



Chethan A J

Assistant Director - QA & RA, Center for Ocular Regeneration (CORE), Brien Holden Eye Research Center (BHERC)

Vaccine World Asia Congress 2026

1:55

Navigating Clinical Trials in Indonesia: Insights and Partnerships for Chinese and Local Stakeholders

- Practical experiences and lessons learned from conducting Phase 1/2 infants' polio vaccine trials in Indonesia.
- Key regulatory and operational considerations for non-Indonesian sponsors entering the Indonesian market.
- Bridging expectations: Understanding specific requirements from China to streamline cross-border collaborations.



Xiaoyuan Zhao

International Clinical Project Management Expert, R&D Division, CanSino Biologics Inc.

Biologics World Asia Congress 2026

2:05

Accelerating Biologics R&D: A Strategic Roadmap for Computational Engineering

- Navigating Multi-Parameter Optimization Trade-Offs: Biologics design requires balancing multiple properties, as optimizing target affinity can compromise critical attributes such as protein stability and selectivity
- Real-World Computational Case Studies: Demonstrating the application of physics-based modelling to large-scale mutagenesis, cross-reactivity screening, multi-parameter ideation, and addressing developability challenges
- Reducing Experimental Cycles and Development Risk: Predicting protein stability and binding energy to support candidate selection, minimize laboratory iterations, and accelerate the development of therapeutic biologics



Abhijit Kayal

Senior Scientist II, Schrodinger

2:20

Speed vs. Compliance: Balancing Agility and Regulatory Rigor in Clinical Development

- Maintaining data integrity while accelerating trial timelines
- Risk-based approaches to regulatory review and monitoring
- Adaptive trial designs and their regulatory acceptance in Asia
- Managing variability in country-specific regulatory expectations



Indriana Permatasari

Project Manager, International Vaccine Institute (IVI)

2:20

Reinventing the Quality Function: From Quality Assurance to Quality Intelligence

- Using AI to automate repetitive quality tasks and investigations
- Moving from periodic audits and inspection to predictive and continuous assurance
- Leveraging AI driven quality metrics to support faster, smarter decision making



Vipul Doshi

Chief Quality and Compliance Officer, Zydus Lifesciences

Vaccine World Asia Congress 2026

2:45

Afternoon Tea Break, Exhibition Viewing
& 1-1 Attendee Networking



Scaling
Biomanufacturing
Capacity &
Technology
Transfer Across SEA

3:40

From Technology Transfer to
Flexible Manufacturing: Building
Scalable Vaccine Capacity in
Southeast Asia

- Translating technology transfer into clear manufacturing, process and GMP requirements
- Designing for scale and flexibility, with modular manufacturing concepts and single-use technologies as key enablers
- Building future-ready manufacturing capacity that can adapt to different vaccine platforms, production volumes and evolving regional demand



Claire Chong

Technical application manager, Tofflon
Science and Technology Group Co., Ltd.

Biologics World Asia Congress 2026

2:45

Afternoon Tea Break, Exhibition Viewing
& 1-1 Attendee Networking



Clinical Adoption,
Reimbursement &
Market Access for
Therapeutic
Biologics

3:30

Generating Actionable Evidence:
Medical Affairs as the Architect of
Value in Biologics Access

- Addressing financial & access barriers to biologics in southeast asia
- Generating evidence to accelerate post launch access
- Building a unified medical affairs evidence strategy



Deepak Mukherjee

Country Medical Director, Roche

Vaccine World Asia Congress 2026

4:05

Winning the race to the market: The blueprint for flawless tech transfer

- Technical complexity and knowhow
- Hard and soft infrastructure
- Operational challenges
- Regulatory bottlenecks



Badarulhisam Abdul Rahman, PhD
Chief Scientific Officer, Pharmaniaga Berhad

Biologics World Asia Congress 2026

3:55

Fireside Chat: From Development to Adoption: Advancing Access to Innovative Biologics

- What are the key challenges in translating innovative biologics from clinical development into real-world clinical practice?
- How can clinical evidence, quality, and regulatory strategies better support clinical adoption and patient access?
- What can industry, healthcare providers, and policymakers do to build sustainable pathways for innovative biologics across Southeast Asia?

MODERATOR

Chethan A J



Assistant Director - QA & RA, Center for Ocular Regeneration (CORE), Brien Holden Eye Research Center (BHERC)

PANELISTS

Deepak Mukherjee



Country Medical Director, Roche

Vaccine World Asia Congress 2026

4:30

Tech Transfer: Vaccines Accessibility and Affordability

- Accelerating technology transfer to strengthen local and regional vaccine manufacturing capacity
- Overcoming technical, regulatory and knowledge-transfer barriers to enable faster scale-up
- Reducing manufacturing costs to improve vaccine affordability and accessibility
- Building sustainable partnerships between vaccine developers, manufacturers and governments

**Prasen Adya**

Deputy Director, Serum Institute of India

4:55

Chairman Closing Remarks**Prasen Adya**

Deputy Director, Serum Institute of India

5:00

END OF CONFERENCE - DAY 1

Biologics World Asia Congress 2026

4:25

Building Sustainable Market Access Pathways for Innovative Biologics in Asia (TBC)**Reserved for Vaibhav Dubey**

Senior General Manager, Sun Pharmaceuticals

4:50

Chairman Closing Remarks**Butet Manurung**Managing Director, Jakarta
Biopharmaceutical Industry (JBio)

4:55

END OF CONFERENCE - DAY 1

Day 2

15 October 2026

8:50

IMAPAC Opening Remarks

8:55

Chairman Opening Remarks



Indriana Permatasari

Project Manager, International Vaccine Institute (IVI)

8:55

Chairman Opening Remarks



Syifa Mutiara Hersista

Digital Tech Research Manager, Bio Farma



mRNA, Viral Vector & Novel Platforms for Fast-Response Vaccines



Bioprocessing & Manufacturing Innovation in Southeast Asia

9:00

mRNA Portfolios After COVID: From Breakthrough Breakthroughs to Sustainable Vaccine Platforms

- How mRNA developers are transitioning from emergency-use success to scalable, multi-indication vaccine pipelines
- Advancing mRNA applications across infectious diseases, oncology, and personalized vaccines
- Comparing strengths, limitations, and hybrid strategies for rapid-response vaccine development
- Building resilient, cost-effective mRNA production and supply chains for global deployment



Dr. Indra Rudiansyah

Project Lead, mRNA Vaccine Programme, Bio Farma

9:00

Strengthening Regulatory Oversight & GMP Readiness for Advanced Biologics Manufacturing in Asia

- Key regulatory challenges and opportunities in biologics manufacturing
- Enhancing GMP readiness and inspection capabilities for advanced modalities
- Lessons learned from regional regulatory convergence and PIC/S activities
- Strategies to strengthen manufacturing quality, compliance, and continuous improvement



Shanti Marlina Sibuea

Acting Director of Production Control of Drugs, Narcotics, Psychotropics, and Precursors, Indonesian National Agency of Drug and Food Control (Badan POM/BPOM)

9:25

Advancing Indonesia's Dengue Vaccine Innovation: Lessons from the Development of a Tetravalent mRNA Dengue Vaccine Prototype

- The journey behind developing Indonesia's tetravalent mRNA dengue vaccine prototype
- How academia, industry and government collaboration can accelerate homegrown vaccine R&D
- Opportunities and challenges in applying mRNA technology to dengue vaccine development
- Translating local vaccine innovation into clinical development, regulatory pathways and future access



M. Indra Lamora

Director – Anti Infectious Department, Etana Biotechnologies

9:25

Driving Acceleration in Insulin and GLP-1 Projects

- GLP-1 and biologics market trends shaping injectable drug delivery
- Patient-centric delivery solutions for self-injection
- De-risking and accelerating combination product development
- BD's technical, testing and regulatory support from concept to market



Sophie Lam

Regional Business Manager, BD Southeast Asia Biopharma System

9:50

Panel Discussion: Fast-Response Vaccines: Are Platform Technologies Ready for the Next Pandemic?

- Comparing speed, scalability, and flexibility of mRNA vs viral vectors
- Key bottlenecks in rapid design-to-deployment timelines
- Lessons from COVID-19: what worked, what didn't
- Building platform readiness for future outbreak scenarios

MODERATOR



Badarulhisam Abdul Rahman, PhD

Chief Scientific Officer, Pharmaniaga Berhad

PANELISTS



Dr. Indra Rudiansyah

Project Lead, mRNA Vaccine Programme, Bio Farma



M. Indra Lamora

Director – Anti Infectious Department, Etana Biotechnologies



Dr. Seyed Reza Banihashemi

Director of R&D, Razi Vaccine & Serum Research Institute



Dr. Martina Ochs

Programme Leader – RNA Programme, CEPI

9:40

AI for Biologics Innovation: From Intelligent Vaccine Design to Data-Driven Manufacturing

- AI Opportunities in Biologics Innovation
- Scaling AI from R&D to Manufacturing
- Overcoming Data, Validation & Regulatory Challenges



Syifa Mutiara Hersista

Digital Tech Research Manager, Bio Farma

10:05

Bioprocessing & Manufacturing Innovation in Southeast Asia

- Shift to Advanced Biologics and Vaccines: Transitioning from traditional generic drug manufacturing to high-value therapeutics, including monoclonal antibodies, biosimilars, and mRNA vaccine platforms
- Geographical Specialization and Stratification: Positioning regional markets as specialized R&D and CDMO hubs, leveraging strong institutional frameworks, abundant biomass, and large domestic markets to advance precision fermentation and vaccine self-sufficiency
- Adoption of Next-Generation Modular Technologies: Overcoming infrastructure limitations through flexible single-use bioreactors, continuous processing, and AI-driven process analytical technology (PAT) to achieve cost-effective manufacturing while maintaining international quality and compliance standards



Butet Manurung

Managing Director, Jakarta
Biopharmaceutical Industry (JBio)

10:40

Morning Tea Break, Exhibition Viewing & 1-1 Attendee Networking

10:30

Morning Tea Break, Exhibition Viewing & 1-1 Attendee Networking



Vaccine Showcase: Emerging & Re- Emerging Infectious Diseases in South East Asia



CDMO & Technology Transfer Partnerships in Southeast Asia

11:20

RSV Prevention in Infants: Translating Clinical Evidence into Population-Level Protection

- Latest clinical and real-world evidence on RSV disease burden and vaccine effectiveness in infants and young children
- Understanding the impact of RSV prevention on hospitalizations, healthcare utilization, and long-term pediatric outcomes
- Identifying high-risk populations and strategies to maximize protection during the first years of life
- Translating evidence into national immunization policies and sustainable pediatric vaccination programs



Dr. Nicholas Lim

Medical Head, RSV Vaccines India & Southeast Asia MCO, Sanofi

11:10

Building End-to-End CDMO Capabilities in Southeast Asia: From Tech Transfer to Commercial Supply

- Scaling from clinical to commercial manufacturing within regional CDMOs
- Infrastructure readiness: single-use systems, modular facilities, digitalization
- Ensuring consistency and comparability across sites
- Case studies of successful end-to-end CDMO partnerships



Lutfhi Zarkasyi

Director of Manufacturing, Kalbio Global Medika

11:45

Advancing Plasmodium vivax Vaccine R&D: Addressing an Emerging Infectious Disease Challenge in Southeast Asia

- Understanding the evolving P. vivax burden and its significance across Southeast Asia
- Addressing the scientific challenges of developing vaccines against P. vivax, including its complex life cycle
- Exploring innovative vaccine platforms, antigens and approaches to achieve durable protection
- Accelerating P. vivax vaccine candidates from research and clinical development toward regional access



Dr. Jetsumon Sattabongkot Prachumsri

Director, Mahidol Vivax Research Unit, Mahidol University

11:35

Accelerating GMP Readiness in SEA: Infrastructure, Quality Systems, and Compliance

- Establishing GMP-compliant facilities aligned with global regulatory standards
- Building QA/QC systems and inspection readiness (FDA, EMA, PIC/S)
- Workforce training and capability development for biologics manufacturing
- Common pitfalls in facility qualification and validation



Rakhmat Budi Yuwono

Quality Director, Etana Biotechnologies

12:00

Regulatory Updates on the Biologics Product Licensing Pathway in India

- Updates to the similar biologics' guidelines
- Digital transformation drive at CDSCO
- Legislative reforms on the horizon



Bobby George

Senior Vice President, Head Regulatory Affairs, Reliance Life Sciences

12:25

Lunch, Exhibition Viewing & 1-1 Attendees Networking

12:25

Lunch, Exhibition Viewing & 1-1 Attendees Networking



Vaccine Distribution & Cold Chain

SESSION CHAIR



Dr. Jetsumon Sattabongkot Prachumsri
Director, Mahidol Vivax Research Unit, Mahidol University



Future Modalities: Next-Generation Cell & Advanced Biologics

1:40

Scaling Vaccine Manufacturing in Southeast Asia: Strengthening Capacity, Digitalisation & Supply Reliability

- Scaling manufacturing capacity while maintaining GMP and product quality
- BCG vaccine manufacturing as a case study in managing biological complexity and process robustness
- Digitalisation and eBR to strengthen data integrity, process control and manufacturing efficiency
- Building reliable and resilient vaccine supply through operational excellence and technology transfer



Yuli Fitriyani Syoemantri
Head of BCG Vaccine Production Department, Bio Farma

1:40

Clinical Development of CAR-T Cell Therapy: Manufacturing, Formulation, Administration & Quality Control

- Key Considerations for CAR-T Cell Therapy Development
- Overview of the CAR-T Cell Manufacturing Process
- Phase I Clinical Trial of UWC19 in R/R B-NHL



Cheng Yi (Jerry) Kuo
Vice General Manager, UWELL Biopharma

2:05

Beyond Approval: Scaling Awareness, Access, and Sustainable Uptake of New Vaccines

- Improving public awareness and vaccine confidence
- Expanding access through innovative funding and reimbursement models
- Addressing affordability and health equity challenges
- Strengthening stakeholder collaboration to drive adoption
- Ensuring long-term sustainability of vaccination programs



Zainab Sadat

General Manager, Vaccines, Southeast Asia & India MCO, Sanofi

2:05

Applications of Regenerative Secretome Technology & Peptides in Functional Health

- Next-generation stem cell technology: cell-free, scalable, and cost-effective approaches
- The shift towards personalised early intervention
- Targeted applications in medical wellness



Kurt Wee

Chief Executive Officer, Celligenics

2:30

Reducing Vaccine Wastage: Inventory Management and Demand Forecasting in Cold Chain Systems

- Improving demand planning and stock allocation accuracy
- First-expiry-first-out (FEFO) and inventory tracking systems
- Minimizing overstocking and stockouts across regions
- Role of analytics and AI in supply chain optimization



Dr. Soleh Ayubi

Chief of Country Representative, PATH

2:30

The UCMSC Secretome: A Cell-Free Hydrogel for Tissue Regeneration in Chronic Wounds

- Dual Bioactivity: Anti-inflammatory and anti-fibrotic effects of the UCMSC secretome through macrophage polarization and reduction of TGF- β -induced α -SMA expression
- Clinical Efficacy: Evaluation of secretome hydrogel in chronic wound healing, including complete epithelialization within 5 days in a 64 cm² wound
- Advantages of Cell-Free Therapy: An off-the-shelf, serum- and antibiotic-free formulation with an 18-month shelf life, offering potential advantages in safety, scalability and regulatory development compared with live-cell therapies



Sandy Qlintang

President Director, Bifarma Adiluhung

2:55

Advancing Immunology, Innovation & Bioprocessing for Future Vaccines

(TBC)



Reserved for Dr. Seyed Reza Banihashemi

Director of R&D, Razi Vaccine & Serum Research Institute

2:55

Afternoon Tea Break, Exhibition Viewing & 1-1 Attendee Networking

3:20

Afternoon Tea Break, Exhibition Viewing & 1-1 Attendee Networking



Leadership Panel: Can Southeast Asia Become a Global Biomanufacturing Powerhouse?

4:00

Leadership Panel: Can Southeast Asia Become a Global Vaccine & Biomanufacturing Powerhouse?

- What will it take for Southeast Asia to become a leading hub for vaccine and biologics manufacturing?
- How can governments and industry accelerate investments in talent, infrastructure, and advanced manufacturing capabilities?
- What role can regional collaboration play in strengthening supply chain resilience and reducing reliance on imports?

MODERATOR



Shanti Marlina Sibuea

Acting Director of Production Control of Drugs, Narcotics, Psychotropics, and Precursors, Indonesian National Agency of Drug and Food Control (Badan POM/BPOM)

PANELISTS



Dr. Neni Nurainy

Head of Translational Development of Life Science Product, Bio Farma



Butet Manurung

Managing Director, Jakarta Biopharmaceutical Industry (JBio)

4:40

Enabling Next-Generation Biologics Manufacturing in Southeast Asia Through Innovation & Strategic Partnerships (TBC)



Reserved for Yagna Praveen

Asst Vice President, Head of Strategic Research, Pharmaniaga

5:05

Chairman Closing Remarks



Syifa Mutiara Hersista

Digital Tech Research Manager, Bio Farma

5:10

END OF CONFERENCE

Expected Audience Snapshot


60%

VACCINE & BIOLOGICS BIOPHARMA


80%

DECISION MAKERS

BY PROFILE



BY JOB TITLE



BY GEOGRAPHY

35%

Singapore,
Thailand, Malaysia,
Laos & Vietnam

25%

Indonesia

25%

China, Taiwan,
Korea & Japan

10%

Australia, India &
Hong Kong

5%

USA & Europe

Who Should Sponsor?

COLD CHAIN & TEMPERATURE CONTROLLED TRANSPORT

PACKAGING AUTOMATION

PACKAGING SOLUTIONS/ SEALING SOLUTIONS

VACCINE DELIVERY & FORMULATION TECHNOLOGY PROVIDERS

QA/QC TESTING

CDMO / CMO (CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATIONS)

CELL LINE & VACCINE PLATFORM TECHNOLOGY PROVIDERS

VACCINE PRODUCTION AND DEVELOPMENT

FILL AND FINISH SERVICE PROVIDERS

BIOPROCESSING & MANUFACTURING EQUIPMENT PROVIDERS

ANALYTICAL TESTING & QC LABS

PROCESS DEVELOPMENT & CDMOS

CLINICAL RESEARCH ORGANIZATIONS (CROS)

PASSIVE PACKAGING SUPPLIERS

LOGISTICS COMPANIES

PROCESS DEVELOPMENT & CDMOS

RAW MATERIALS & REAGENTS SUPPLIERS

REGULATORY AFFAIRS & CONSULTING

Why Sponsor This Event?

Thought Leadership

Present Your Expertise to the Biopharma Industry's Key Stakeholders through a Variety of Available Speaking Packages.

Host a Panel Discussion

Moderate a panel discussion including one representative from your company with 3 representatives from the end user side to share views on a current industry topic

Duration: 45 minutes

Showcase Your Solutions to Educate the Market

Join in for dedicated CMO & CRO Showcases

Branding

Emphasize on your Message by Marketing and Promoting Alongside the Event

Networking & Lead Generation

Gain Exclusive Access to Contacts of High Profile Attendees through Intimate Networking Opportunities

Our Past Partners



MARK YOUR CALENDAR

Save the Date

14 - 15 **OCT**
2026

📍 Sheraton Grand Jakarta Gandaria City Hotel

VWSEA & BWSEA 2026 Brochure

ALL IMAPAC EVENTS



Explore Our Full Event Calendar

Discover all upcoming and future IMAPAC events across Asia-Pacific: biopharmaceutical conferences, summits and exhibitions for the year ahead.



OR ADD THIS EVENT TO YOUR CALENDAR



Google Calendar

One-click add to Gmail



Outlook Calendar

Add to Microsoft Outlook



Scan to Register

Open camera, point at code, instant registration access.

Or click the QR to open registration directly.

CATEGORY	EARLY BIRD (By 15 May 2026)	REGISTRATION (By 17 July 2026)	STANDARD (By 18 September 2026)	FINAL CALL
BIOPHARMA, ACADEMIC & RESEARCH — BASED IN ASIA (APAC)				
2-Day Conference Pass Job Profiles: Manufacturing, Bioprocessing, Production, USP, DSP, Operations, Site Heads, Drug Substance and Product Manufacturing, Process Development, Quality, Analytics and other related technical designations	SGD 1,495	SGD 1,695	SGD 1,895	SGD 2,095
BIOPHARMA, ACADEMIC & RESEARCH — BASED OUTSIDE OF ASIA				
2-Day Conference Pass Job Profiles: Manufacturing, Bioprocessing, Production, USP, DSP, Operations, Site Heads, Drug Substance and Product Manufacturing, Process Development, Quality, Analytics and other related technical designations	SGD 1,995	SGD 2,195	SGD 2,395	SGD 2,595
BIG PHARMA, SOLUTION / SERVICE / TECHNOLOGY PROVIDERS & CDMO/CMO				
2-Day Conference Pass Business Development, Marketing & Sales profiles	SGD 2,995	SGD 3,195	SGD 3,395	SGD 3,595
BRING YOUR TEAM - Group Discount				
Asia & International Biopharma ☐ Buy 2, Get 3 passes ☐ Buy 3, Get 5 passes Limited to professionals in the "BUYER" profile working in Process Development, R&D, QC & Assurance, Manufacturing Heads, Engineering, Upstream, Downstream or Analytical in Big Pharmas, International / Asian Biopharmas, and Academic & Research Institutes. INNER CIRCLE Speaker referrals and professionals working in the same organisation as our speakers are entitled to a 15% discount. - Access to all conference proceedings for up to 30 days. - Site Tour Package is applicable only with the purchase of a conference pass.				
Standard Package Group Discount				
3 Delegates ☐ Save 10% 5 Delegates ☐ Save 20% 6+ Delegates ☐ Save 25%				

EVENT VENUE



Sheraton Grand Jakarta Gandaria City Hotel, Indonesia
14 - 15 October 2026

3 EASY WAYS TO REGISTER

Online
<https://www.imapac.com/events/vaccine-world-asia-congress-2026---south-east-asia>

Telephone
+65 6983 6140 (SG) / +44 161 552 8507 (UK)

Mail
Cheque payable to IMAPAC Pte Ltd,
36 Robinson Road, #02-01
068877
Singapore

Cheque payable to IMAPAC UK Ltd,
77 Farringdon Road, Farringdon, London
EC1M 3JU
United Kingdom

YOUR DETAILS

Name	
Job Title	Organization
Address	
Postcode	Country
Tel	Fax
Email	
Your primary business	
Authorising Manager	Authorising manager signature

PAYMENT DETAILS

Payment is due immediately upon receipt of this registration form if you pay by credit card or 3 working days after your receipt of payment notification. Non-credit card payment will incur an additional US\$100 (Bank handling fee)

I want to pay:	☐ Credit Card	☐ Bank Transfer	☐ Cheque	Offline credit card:	☐ Visa	☐ MasterCard	☐ American Express
Online credit card payment: Please register at https://www.imapac.com/events/vaccine-world-asia-congress-2026---south-east-asia#register							

Name on Card	Card Number	
Expiry Date (MM/YY)	CVC Code	Signature

TERMS & CONDITIONS

Payment & Registration
Full payment is due upon registration if you pay by credit card, or 3 working days after receipt of invoice. Registration will not be confirmed until full payment has been received. Unpaid registration will be billed 50% of the registration fee if you do not attend the event. A copy of the conference documentation will be mailed to you. Staff at the event will request a credit card guarantee for delegates without proof of payment.

Ticket Classification
All registrations are reviewed to ensure correct classification. Biopharma tickets are reserved for professionals employed by pharmaceutical or biopharmaceutical companies that develop, own or commercialise therapeutic drug products. Service, Solution and Technology Provider tickets apply to organisations offering services, platforms, technologies, equipment, consultancy or manufacturing services to the industry (including CROs, CDMOs, vendors, consultants and suppliers). Purchasing an incorrect ticket does not guarantee entry. IMAPAC retains full discretion to deny access, reclassify registrations and issue an invoice for the price difference. Incorrect ticket purchases under an inappropriate classification are not eligible for refunds under any circumstances.

Cancellation & Substitution Policy
Cancellations must be received in writing. If the cancellation is received more than 14 days before the conference, attendees will receive a full credit note towards a future conference. Cancellations received 14 days or less (including the fourteenth day) prior to the conference will be liable for the full fee. A substitution from the same organisation can be made at any time in writing at no extra charge. In the event that IMAPAC cancels a conference, payments received at the cancellation date will be credited towards attendance at a future conference, or in the event of postponement by IMAPAC, towards the rescheduled date. Credit notes remain valid for twelve months.

Changes to Conference & Agenda
IMAPAC reserves the right to postpone or cancel an event, to change the location or alter the advertised speakers for an event. IMAPAC is not responsible for any loss or damage as a result of substitution, alteration, postponement or cancellation of an event due to causes beyond its control including, without limitation, acts of God, natural disasters, sabotage, accident, trade or industrial disputes, terrorism or hostilities. In the event that a conference is cancelled, IMAPAC is not liable for any costs incurred by delegates in connection with their attendance. Changes to the agenda will be updated on our website as soon as possible.

Data Protection
The personal information shown and/or provided by you will be held in a database. It may be used to keep you up to date with developments in your industry. Sometimes your details may be obtained or made available to reputable third parties for marketing purposes. If you do not wish your details to be used for this purpose, please write to: data@imapac.com.

CATEGORY	EARLY BIRD (By 15 May 2026)	REGISTRATION (By 17 July 2026)	STANDARD (By 18 September 2026)	FINAL CALL
BIOPHARMA, ACADEMIC & RESEARCH — BASED IN ASIA (APAC)				
2-Day Conference Pass Job Profiles: Manufacturing, Bioprocessing, Production, USP, DSP, Operations, Site Heads, Drug Substance and Product Manufacturing, Process Development, Quality, Analytics and other related technical designations	SGD 1,495	SGD 1,695	SGD 1,895	SGD 2,095
BIOPHARMA, ACADEMIC & RESEARCH — BASED OUTSIDE OF ASIA				
2-Day Conference Pass Job Profiles: Manufacturing, Bioprocessing, Production, USP, DSP, Operations, Site Heads, Drug Substance and Product Manufacturing, Process Development, Quality, Analytics and other related technical designations	SGD 1,995	SGD 2,195	SGD 2,395	SGD 2,595
BIG PHARMA, SOLUTION / SERVICE / TECHNOLOGY PROVIDERS & CDMO/CMO				
2-Day Conference Pass Business Development, Marketing & Sales profiles	SGD 2,995	SGD 3,195	SGD 3,395	SGD 3,595
BRING YOUR TEAM - Group Discount				
Asia & International Biopharma ☐ Buy 2, Get 3 passes ☐ Buy 3, Get 5 passes Limited to professionals in the "BUYER" profile working in Process Development, R&D, QC & Assurance, Manufacturing Heads, Engineering, Upstream, Downstream or Analytical in Big Pharmas, International / Asian Biopharmas, and Academic & Research Institutes. INNER CIRCLE Speaker referrals and professionals working in the same organisation as our speakers are entitled to a 15% discount. - Access to all conference proceedings for up to 30 days. - Site Tour Package is applicable only with the purchase of a conference pass.				
Standard Package Group Discount				
3 Delegates ☐ Save 10% 5 Delegates ☐ Save 20% 6+ Delegates ☐ Save 25%				

EVENT VENUE



Sheraton Grand Jakarta Gandaria City Hotel, Indonesia
14 - 15 October 2026

3 EASY WAYS TO REGISTER

Online
<https://www.imapac.com/events/biologics-world-south-east-asia-2026#register>

Telephone
+65 6983 6140 (SG) / +44 161 552 8507 (UK)

Mail
Cheque payable to IMAPAC Pte Ltd,
36 Robinson Road, #02-01
068877
Singapore

Cheque payable to IMAPAC UK Ltd,
77 Farringdon Road, Farringdon, London
EC1M 3JU
United Kingdom

YOUR DETAILS

Name	
Job Title	Organization
Address	
Postcode	Country
Tel	Fax
Email	
Your primary business	
Authorising Manager	Authorising manager signature

PAYMENT DETAILS

Payment is due immediately upon receipt of this registration form if you pay by credit card or 3 working days after your receipt of payment notification. Non-credit card payment will incur an additional US\$100 (Bank handling fee)

I want to pay:	☐ Credit Card	☐ Bank Transfer	☐ Cheque	Offline credit card:	☐ Visa	☐ MasterCard	☐ American Express
Online credit card payment: Please register at https://www.imapac.com/events/biologics-world-south-east-asia-2026#register							

Name on Card	Card Number	
Expiry Date (MM/YY)	CVC Code	Signature

TERMS & CONDITIONS

Payment & Registration
Full payment is due upon registration if you pay by credit card, or 3 working days after receipt of invoice. Registration will not be confirmed until full payment has been received. Unpaid registration will be billed 50% of the registration fee if you do not attend the event. A copy of the conference documentation will be mailed to you. Staff at the event will request a credit card guarantee for delegates without proof of payment.

Ticket Classification
All registrations are reviewed to ensure correct classification. Biopharma tickets are reserved for professionals employed by pharmaceutical or biopharmaceutical companies that develop, own or commercialise therapeutic drug products. Service, Solution and Technology Provider tickets apply to organisations offering services, platforms, technologies, equipment, consultancy or manufacturing services to the industry (including CROs, CDMOs, vendors, consultants and suppliers). Purchasing an incorrect ticket does not guarantee entry. IMAPAC retains full discretion to deny access, reclassify registrations and issue an invoice for the price difference. Incorrect ticket purchases under an inappropriate classification are not eligible for refunds under any circumstances.

Cancellation & Substitution Policy
Cancellations must be received in writing. If the cancellation is received more than 14 days before the conference, attendees will receive a full credit note towards a future conference. Cancellations received 14 days or less (including the fourteenth day) prior to the conference will be liable for the full fee. A substitution from the same organisation can be made at any time in writing at no extra charge. In the event that IMAPAC cancels a conference, payments received at the cancellation date will be credited towards attendance at a future conference, or in the event of postponement by IMAPAC, towards the rescheduled date. Credit notes remain valid for twelve months.

Changes to Conference & Agenda
IMAPAC reserves the right to postpone or cancel an event, to change the location or alter the advertised speakers for an event. IMAPAC is not responsible for any loss or damage as a result of substitution, alteration, postponement or cancellation of an event due to causes beyond its control including, without limitation, acts of God, natural disasters, sabotage, accident, trade or industrial disputes, terrorism or hostilities. In the event that a conference is cancelled, IMAPAC is not liable for any costs incurred by delegates in connection with their attendance. Changes to the agenda will be updated on our website as soon as possible.

Data Protection
The personal information shown and/or provided by you will be held in a database. It may be used to keep you up to date with developments in your industry. Sometimes your details may be obtained or made available to reputable third parties for marketing purposes. If you do not wish your details to be used for this purpose, please write to: data@imapac.com.

A VARIETY OF PRODUCTS TO CATER TO GLOBAL BIOPHARMACEUTICAL INDUSTRY'S MARKET INTELLIGENCE AND BUSINESS CONNECTIONS NEEDS.

01 B2B EVENTS

Thought-leadership, industry knowledge-sharing and quality networking are at the core of IMAPAC's B2B events.

Create an engaging experience for your audiences, explore our B2B Events Solutions.

02 360 MARKETING SOLUTIONS

Expand your reach and influence! Be it with customized events, digital marketing solutions, content creation or thought-leadership.

Tap into our pool of audience that spans across various sub-sectors and regions critical in the burgeoning APAC biopharmaceutical sector.

03 DASHBOARDS

A quick-view analytics tool to power your decisions. Access region or country-specific data to uncover pipeline information, product focus.

Customize the dashboard based on your needs. Drill down to the data you need using custom views.

04 CUSTOM RESEARCH

Based on your objectives and budget, you can customize a package to one that best meets your intelligence needs. This allows you to maximize your ROI without spending on items that are not in line with your strategies.

With access to a database of 60,000+ life science professionals. We conduct research with a highly-qualified audience.

05 REPORTS

Discover in-depth market information of the growing biopharmaceutical sector.

[Learn More →](#)



HELPING THE GLOBAL BIOPHARMACEUTICAL INDUSTRY

Generate Tangible Growth

IMAPAC is the one-stop shop of market intelligence and business connections for the global biopharmaceutical industry. We help companies expand their influence, make data driven decisions through our industry intelligence, and link up with other biopharmaceutical professionals to exchange knowledge and engage in quality networking. At the

core of IMAPAC is our mission to help biopharmaceutical businesses globally generate tangible growth. At the same time, our heart lies in giving back to society. We empower the next generation by equipping underprivileged children with an education.

WEBSITE

imapac.com

EMAIL

info@imapac.com

IMAPAC PTE LTD

36 Robinson Road, #02-01
Singapore 068877
+65 6983 6140

IMAPAC UK LTD

77 Farringdon Road, Farringdon
London EC1M 3JU, United Kingdom
+44 161 552 8507

CONNECT WITH US

LINKEDIN

@imapac

X

@imapac

FACEBOOK

ImapacPteLtd